期刊文献+

消癌平联合热疗对耐吉非替尼人肺癌A549细胞的抑制作用及其血管内皮生长因子表达的影响 被引量:2

下载PDF
导出
摘要 目的:研究消癌平与热疗联合对耐吉非替尼人肺腺癌细胞株A549的抑制作用,以及对细胞中血管内皮生长因子(VEGF)表达的影响。方法:以体外培养的耐吉非替尼人肺腺癌细胞株A549,用噻唑兰(MTT)检测其增殖抑制作用;用RT-PCR方法检测细胞中VEGF基因表达;用ELISA法检测细胞中VEGF蛋白含量。结果:消癌平单药抑制率为12%,高温组抑制率为12%,消癌平联合高温组抑制率为45%,差异有统计学意义(P<0.05);消癌平单药VEGF表达为78.95%,高温组为37.02%,消癌平联合高温组为24.82%,差异有统计学意义(P<0.05);消癌平单药VEGF蛋白含量表达为60.87%,高温组为4.78%,消癌平联合高温组为0.35%,差异有统计学意义(P<0.05)。结论:消癌平联合热疗可抑制A549肺癌细胞的增殖,其作用机制可能与降低VEGF蛋白表达介导肿瘤血管生成有关。
出处 《浙江中医杂志》 2016年第6期414-415,共2页 Zhejiang Journal of Traditional Chinese Medicine
  • 相关文献

参考文献7

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J].CA Cancer J Clin. 2013(63):11-30. 被引量:1
  • 2Petrillo i, Borriello M, Fuoco G, et alNovel VEGF- independent Strategies Targeting Tumor Vasculature: Clinical Aspects[J].Current Pharmaceutical Design, 2012,18:2702-2712. 被引量:1
  • 3Huang Z, Lin H, gang Y, Cao anti-angiogenic effect of Mar tract in vitro and in vivo[J] 917-922. Z, et sden al. Studies on the la Oncol tenacissima ex Lett,2013,5(3). 被引量:1
  • 4梁晓华,高广辉,周鑫莉,蒋京伟,黄若凡,初钊辉,林浩,詹琼.消癌平注射液抗C57小鼠Lewis肺癌肿瘤血管生成的研究[J].临床肿瘤学杂志,2010,15(8):689-692. 被引量:21
  • 5葛淑瑜,陈建,张家建,陈永利.消癌平逆转厄洛替尼非小细胞肺癌耐药的作用机制研究[J].浙江中医杂志,2014,49(7):532-534. 被引量:10
  • 6Chatterjee S, Heukamp LC, Siobal M, et al. Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers an- giogenesis in lung cancer[J].J Clin Invest,2013,123 (4):1732-1740. 被引量:1
  • 7Yi ZF, Cho SG, Zhao H, et al.A novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c-Src phosphorylation in VEGF induced human umbilical endothelial cellsEJ]. Int J Cancer,2009,124(4):843-852. 被引量:1

二级参考文献17

  • 1钱军,华海清,秦叔逵.通关藤制剂抗肿瘤作用研究进展[J].中国中药杂志,2009,34(1):11-13. 被引量:29
  • 2.lemal A, Siegel R, Ward E, et al. Cancer statistics, 2008 [ J ]. CA Cancer J Clin,2008,58(2) :71 -96. 被引量:1
  • 3Novello S, Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 1 : Early-stage Disease [ J ]. Oncology ( Williston Park) ,2003,17 ( 3 ) :357 - 364. 被引量:1
  • 4Folkman J. Clinical applications of research on angiogenesis[ J]. N Engl J Med, 1995,333 (26) : 1757 - 1763. 被引量:1
  • 5Pate1 NS, Dobbie MS, Rochester M, et al. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer [ J ]. Clin Cancer Res, 2006, 12 ( 16 ) : 4836 - 4844. 被引量:1
  • 6Folkman J. Tumor angiogenesis : therapeutic implications [ J ]. N Engl J Med,1971, 285(21) :1182 - 1186. 被引量:1
  • 7Hanahan, Folkman J. Patterns and emerging mechanisms of the angiogenie switeh during tumorigenesis [ J ]. Cell, 1996,86 ( 3 ) : 353 - 364. 被引量:1
  • 8Cross M J, Claesson - Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition [ J ]. Trends Pharmacol Sci ,2001,22 (4) :201 - 207. 被引量:1
  • 9Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and 21 mutations treated with gefitinib or erlotinib[J].Clin Cancer Res, 2006,12 : 839- 845. 被引量:1
  • 10Okabe T, Okamoto I, Tsukioka S, et al.Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinih resistance in non-small cell lung cancer cell lines with MET amplification[J].Clin Cancer Res,2009,15 : 907-913. 被引量:1

共引文献27

同被引文献83

引证文献2

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部